Phase 4 Alopecia Areata Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and teenagers between 2 and 17 years old
- People who have been diagnosed with alopecia areata (a condition causing hair loss) by a qualified skin specialist (dermatologist)
- For participants aged 12–17, both the young person and their parents or guardians must be willing to give consent to take part; for children under 12, parents or guardians provide consent on their behalf
Who may not be able to join:
- People who would not be able to follow the study requirements, such as taking medication as directed, attending clinic appointments, and completing questionnaires
- People with poor kidney function (confirm with trial site)
- People with high blood pressure that is not well controlled
- People with an active infection at the time of joining
- People who have or have had a cancer diagnosis
- People with a kidney condition called nephrotic syndrome combined with poorly controlled high blood pressure, active infection, or cancer
- People with kidney disease, except in certain cases of nephrotic syndrome with mild to moderate kidney problems (confirm with trial site)
- People who are pregnant, trying to conceive (applies to both male and female participants), or who are breastfeeding
- People with severe kidney or liver disease, liver scarring (fibrosis or cirrhosis), or problems related to heavy alcohol use
- People with bone marrow problems, a weakened immune system, or immune deficiency conditions
- People with low red blood cell counts (anaemia), low white blood cell counts (leukopenia), or low platelet counts (thrombocytopenia)
- People who are in poor nutritional health, such as having low levels of a protein called albumin in their blood
- People who have a known allergy or sensitivity to the medication methotrexate (MTX)
- People who have previously experienced lung damage related to methotrexate, or who have significantly reduced lung function
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (010) 704 01 10
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
SALT 36 weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.